CRVS - CIK 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $40.10M | $2.87M | $14.69M | $5.00M | $4.68M | $14.84M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $43.00K | $32.00K | $86.00K | $79.00K | $70.00K | $35.00K |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $239.95M |
| $66.94M |
| $75.78M |
| $45.49M |
| $42.92M |
| $48.26M |
| Property, plant & equipment | $282.00K | $221.00K | $249.00K | $165.00K | $171.00K | $192.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $253.19M | $80.47M | $89.46M | $59.44M | $58.81M | $64.56M |
| Accounts payable | $4.70M | $1.97M | $3.14M | $1.31M | $1.87M | $1.21M |
| Total current liabilities | $12.11M | $8.07M | $8.51M | $9.28M | $46.41M | $13.34M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $12.52M | $8.71M | $9.23M | $10.11M | $46.41M | $13.34M |
| Retained earnings | -$425.99M | -$399.97M | -$389.81M | -$381.82M | -$384.90M | -$344.68M |
| Total equity | $240.68M | $71.77M | $80.23M | $49.33M | $12.41M | $51.23M |